Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency

@article{Lim2006MetaAnalysisLH,
  title={Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency},
  author={Wendy Lim and Francesco Dentali and John W Eikelboom and Mark Andrew Crowther},
  journal={Annals of Internal Medicine},
  year={2006},
  volume={144},
  pages={673-684}
}
Context The risks of low-molecular-weight heparin (LMWH) in patients with severe renal insufficiency are not clear. Contribution In this review of 12 studies, patients with severe renal insufficiency receiving LMWH had an increased risk for major bleeding events. Four studies found that fixed-dose enoxaparin had greater anticoagulant effects in these patients. Three studies suggested that empirically dose-adjusted enoxaparin might not increase anticoagulant effects. Cautions Evidence relating… Expand

Paper Mentions

Observational Clinical Trial
The purpose of this study is to assess if accumulation of anti-Xa activity occurs after repeated daily administration of prophylactic doses of tinzaparin in patients with severe… Expand
ConditionsDeep Venous Thrombosis, Protection Against, Renal Insufficiency, Chronic
InterventionDrug
Interventional Clinical Trial
Fondaparinux is a parenteral anticoagulant drug and is approved for the prevention of venous thromboembolism in high risk medical patients. A relevant proportion of medical patients… Expand
ConditionsMedical Patients, Renal Insufficiency
InterventionDrug
Low-molecular-weight heparin in patients with chronic renal insufficiency
  • W. Lim
  • Medicine
  • Internal and emergency medicine
  • 2008
TLDR
Low-molecular-weight heparin must be used carefully in patients with renal insufficiency, particularly in those with severe renal impairment, and LMWHs with a higher molecular weight may be less prone to accumulation and bleeding. Expand
Use of Low-Molecular-Weight Heparins and New Anticoagulants in Elderly Patients with Renal Impairment
TLDR
Clinical evidence suggests that treatment with full-dose enoxaparin sodium could increase the risk for bleeding in elderly patients with severe renal impairment; however, this risk is ameliorated with approved dose adjustments. Expand
Differences among Various Low-Molecular-Weight Heparins in Patients with Severe Renal Insufficiency: An Analysis of Recent Clinical Trials
TLDR
Dalteparin and tinzaparin, when used at prophylactic doses, does not bioaccumulate and can be used safely in patients with severe renal impairment, and these differences may be explained by the fact that smaller LMWH chains are cleared primarily by the kidneys, whereas larger chains have greater clearance by nonrenal mechanisms. Expand
ANTICOAGULANT TREATMENT IN PATIENTS WITH RENAL INSUFFICIENCY
TLDR
Recommendations on use of anticoagulant drugs in patients with renal insufficiency are summarized and management of these patients before and after invasive nephrological procedures including renal transplantation is suggested. Expand
Anticoagulation: Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings
TLDR
Practical recommendations for the use of low-molecular-weight heparins as prophylaxis and treatment of venous thromboembolism and acute coronary syndromes in patients with impaired renal function or obesity are developed. Expand
Low molecular weight heparin a nd bleeding in patients with chronic renal failure
Purpose of review Low molecular weight heparin (LMWH) has largely replaced unfractionated heparin (UFH) in patients with venous thromboembolism because of its pharmacokinetic profile, ease ofExpand
Low molecular weight heparin and bleeding in patients with chronic renal failure.
TLDR
Care should be used when LMWHs are administered to patients with impaired renal function, particularly those with severe impairment (creatinine clearance below 30 ml/min). Expand
Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
TLDR
Obese patients have a lower proportion of lean body mass as a percentage of total body weight, and because obese patients are already at higher risk of VTE recurrence, they may be particularly sensitive to subtherapeutic anticoagulation. Expand
Using low molecular weight heparin in special patient populations
  • W. Lim
  • Medicine
  • Journal of Thrombosis and Thrombolysis
  • 2009
TLDR
Concerns about possible underdosing of prophylactic dose LMWH in obese individuals using the standard fixed doses, particularly in the extremely obese individuals undergoing bariatric surgery and pregnancy poses challenges with regards to the safety of LM WH during pregnancy and use of LMWH around delivery. Expand
Dosage reduction of low weight heparin in patients with renal dysfunction: Effects on anti-Xa levels and clinical outcomes
TLDR
Pre-emptive dosage reduction of LMWH leads to low anti-Xa levels in a large proportion, but this was not associated with bleeding, thrombosis or mortality. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 60 REFERENCES
Is impaired renal function a contraindication to the use of low-molecular-weight heparin?
TLDR
The use of a 30-mL/min (0.50- mL/s) cutoff of creatinine clearance is not justified, on the basis of currently available evidence, to select individuals at increased risk of accumulation when LMW heparin is used. Expand
Is laboratory monitoring of low‐molecular‐weight heparin therapy necessary? Yes
  • J. Harenberg
  • Medicine
  • Journal of thrombosis and haemostasis : JTH
  • 2004
TLDR
Clinical trials indicate that the interpatient variability is less pronounced for LMWHs, leading to less frequent dose adjustments in a small proportion of patients for treatment of VTE compared with UFH, indicating a clear association between plasma activities and side-effects. Expand
Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials.
TLDR
Fixed-dose low-molecular-weight heparin treatment appears to be as effective and safe as dose-adjusted intravenous unfractionated heparIn for the initial treatment of nonmassive pulmonary embolism. Expand
Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes.
TLDR
The aims of this study were to investigate the influence of glomerular filtration rate (GFR) on the pharmacokinetics of subcutaneously administered enoxaparin, and to develop a practical dosing algorithm in renal impairment that can easily be used at the bedside. Expand
Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin.
TLDR
Both the twice-daily enoxaparin and UFH regimens are associated with comparable increases in major bleeding complications in patients with renal dysfunction receiving full-dose anticoagulation therapy. Expand
Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease.
  • V. Farooq, J. Hegarty, +7 authors G. Wood
  • Medicine
  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2004
TLDR
LMWHs administered at fixed-weight doses and without monitoring show unpredictable anticoagulant effects in patients with chronic kidney disease stages 4 and 5, leading to serious and even fatal adverse incidents. Expand
Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With Enoxaparin
TLDR
In this large unselected cohort of patients with UA/NSTEMI patients, low anti-Xa activity on enoxaparin treatment is independently associated with 30-day mortality, which highlights the need for achieving at least the minimum prescribed anti- Xa level of 0.5 IU/mL with enoxAParin whenever possible. Expand
Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials.
TLDR
Low-molecular-weight heparins treatment reduces mortality rates after acute deep venous thrombosis and seems to be as safe as unfractionated heparin with respect to major bleeding complications and as effective in preventing thromboembolic recurrences. Expand
Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome.
TLDR
The use of enoxaparin was suboptimal, with the potential to increase bleeding complications, and coadministered clopidogrel, other drugs that affect hemostasis, and increasing age conferred an increased bleeding risk. Expand
Low Molecular Weight Heparin for the Prevention of Deep Venous Thrombosis: A Suitable Monitoring in Elderly Patients?
TLDR
The findings question the opportunity to monitor aXa in elderly patients receiving 4,000 IU enoxaparin as antithrombotic prophylaxis, and a negative relationship between a Xa and body weight and a trend towards a positive correlation between aXA and age but not with creatinine clearance were noted. Expand
...
1
2
3
4
5
...